Avenge Bio
Por um escritor misterioso
Last updated 20 setembro 2024
Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors.
Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies.
The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio Archives - THELANSIS
Avenger Organic Weed Killer
Avenge Bio secures FDA designation for mesothelioma therapy
avengebio (@AvengeBio) / X
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
How far would YOU go to avenge a friend? 😈 Details on this insane story at link in bio, link in Stories, or go here:…
Avenger Natural Weed Killer
Avenge Bio Appoints Douglas Carlson as Chief Operating and Financial Officer
Biotech, Pharmaceutical and Clinical Research News
New pinhead-sized beads kill ovarian, colorectal cancers by producing interleukin-2: mouse study
Recomendado para você
você pode gostar